Edward Kong-Hwa Li
Affiliations: | 1991 | Materials Science | University of Rochester, Rochester, NY |
Google:
"Edward Li"Parents
Sign in to add mentor| Paul D. Funkenbusch | grad student | 1991 | Rochester | |
| (Initial packing and densification rates of monosized and bimodal-sized particle systems during hot isostatic pressing (HIP)) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Carroll SH, Schafer S, Kawasaki K, et al. (2024) Genetic requirement of to regulate noncanonical Wnt signaling and during embryonic convergent extension and craniofacial morphogenesis. Elife. 13 |
| Chaplin S, van Stiphout J, Chen A, et al. (2024) Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective. Journal of Managed Care & Specialty Pharmacy. 1-13 |
| Li E, Goh A, Gupta S, et al. (2024) Budget impact analysis of biosimilar natalizumab in the US. The American Journal of Managed Care. 30: e191-e197 |
| Li E, Russon A, Chen J, et al. (2024) Small Cell Neuroendocrine Carcinoma of the Prostate on 18 F-DCFPyL and 18 F-FDG PET/CT. Clinical Nuclear Medicine. 49: 335-337 |
| Carroll SH, Schafer S, Kawasaki K, et al. (2023) modifies noncanonical Wnt signaling and expression to regulate convergent extension and craniofacial development. Biorxiv : the Preprint Server For Biology |
| Li E, Anand Kumar R, Chen J, et al. (2023) False-Positive Metastatic Disease Due to Bilateral Ectopic Adrenal Tissue. Clinical Nuclear Medicine |
| Schauf M, Chinthapatla H, Dimri S, et al. (2023) Economic burden of multiple sclerosis in the United States: A systematic literature review. Journal of Managed Care & Specialty Pharmacy. 1-15 |
| Aslam S, Li E, Bell E, et al. (2023) Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis. Journal of Managed Care & Specialty Pharmacy. 29: 128-138 |
| Campbell K, Chadha N, Dimri S, et al. (2022) G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. Expert Review of Hematology. 1-15 |
| Li E, Schroader BK, Campbell D, et al. (2021) The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis. Journal of Health Economics and Outcomes Research. 8: 106-115 |